Recent Advances in Patient Treatment and Care (Track)
CCMP, a new road for the treatment of monogenic diseases due to mutations; its use on chemo-resistant cancers
M. Raafat El-Gewely, Ph.D. Institute of Medical Biology, University of Tromsø, 9037 Tromsø, Norway
Abstract:
In contrast to gene therapy, our novel approach, Conformation Correction of Mutated Proteins (CCMP), patents pending, does not use DNA vectors and does not depend on gene targeting. As accurate molecular diagnostics is exponentially increasing, our new technology platform is ideal to be implemented for the potential treatment of diseases caused by point mutations with debilitating effects on protein function.
In my talk I will focus on the use of our proprietary approach to develop CCMP therapeutics for a specific mutation in tumor suppressor gene (p53). These mutations can lead to metastatic cancers that are resistant to common chemotherapy. Our lead compounds are not toxic to normal cells and the down stream gene expression of treated mutated cell lines reflects the restoration of p53 activities.
CCMP approach appears to be efficient, cost effective and safer alternative to gene therapy for the treatment of metastatic chemoresistant cancers and potentially for monogenic genetic diseases due to mutations.
Animal testing and preclinical studies are starting shortly with an International CRO laboratory.
